Objective:
To determine if early resolution of retinal fluid after initiating faricimab therapy can predict longer treatment intervals in patients with neovascular age-related macular degeneration (nAMD), thereby improving treatment strategies.
Key Findings:
- 265 out of 552 participants achieved resolution of IRF and SRF within the first 12 weeks, with visual outcomes showing a mean best-corrected visual acuity that was numerically similar or slightly better in this group.
Interpretation:
Early anatomical response, indicated by fluid resolution, may serve as a predictor for treatment durability and extended dosing intervals in nAMD patients treated with faricimab, potentially guiding clinical decisions.
Limitations:
- Findings are based on a post hoc analysis, which may limit the strength of the conclusions and introduce bias.
- Further validation in prospective studies is necessary to confirm these findings.
Conclusion:
Identifying early predictors of treatment durability could help tailor treatment strategies, reduce the injection burden for nAMD patients, and improve overall patient care.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
